Why Ionis Pharmaceuticals Inc. Slipped This Morning
Shares of Ionis Pharmaceuticals Inc. (NASDAQ: IONS) dipped 13% lower in early morning trading on Tuesday after its most important collaboration partner reported some disturbing third-quarter sales figures. Although Biogen (NASDAQ: BIIB) recorded a quarter-to-quarter gain in global Spinraza sales, stagnant U.S. sales of the partnered drug suggest it could hit a saturation point earlier than expected. The stock has fallen 10.4% as of 11:03 a.m. EDT on Tuesday.
Ionis has received about $94.4 million from Biogen in the first half of this year in royalty and milestone payments associated with Spinraza, the first and only approved treatment for Spinal Muscular Atrophy. That works out to about 46% of the company's total revenue during the first half of the year.
Image source: Getty Images.
Source: Fool.com
Biogen Inc. Aktie
Hohe Buy- und niedrige Sell-Zahlen bei Biogen Inc. zeigen ein stark positives Sentiment.
Das Community-Kursziel von 200 € für Biogen Inc. deutet auf ein leicht positives Wachstumspotenzial gegenüber 179.9 € hin.
